244 related articles for article (PubMed ID: 15846671)
41. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.
Angelico F; Burattin M; Alessandri C; Del Ben M; Lirussi F
Cochrane Database Syst Rev; 2007 Jan; (1):CD005166. PubMed ID: 17253544
[TBL] [Abstract][Full Text] [Related]
42. Glucocorticosteroids for primary biliary cirrhosis.
Prince M; Christensen E; Gluud C
Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003778. PubMed ID: 15846681
[TBL] [Abstract][Full Text] [Related]
43. Hepatitis B vaccination for patients with chronic renal failure.
Schroth RJ; Hitchon CA; Uhanova J; Noreddin A; Taback SP; Moffatt ME; Zacharias JM
Cochrane Database Syst Rev; 2004; 2004(3):CD003775. PubMed ID: 15266500
[TBL] [Abstract][Full Text] [Related]
44. Ribavirin monotherapy for chronic hepatitis C.
Brok J; Gluud L; Gluud C
Cochrane Database Syst Rev; 2005 Oct; (4):CD005527. PubMed ID: 16235408
[TBL] [Abstract][Full Text] [Related]
45. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis.
Orlando R; Azzalini L; Orando S; Lirussi F
Cochrane Database Syst Rev; 2007 Jan; (1):CD005160. PubMed ID: 17253541
[TBL] [Abstract][Full Text] [Related]
46. D-penicillamine for primary biliary cirrhosis.
Gong Y; Frederiksen SL; Gluud C
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004789. PubMed ID: 15495127
[TBL] [Abstract][Full Text] [Related]
47. Milk thistle and the treatment of hepatitis.
Giese LA
Gastroenterol Nurs; 2001; 24(2):95-7. PubMed ID: 11847735
[TBL] [Abstract][Full Text] [Related]
48. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis.
Lirussi F; Azzalini L; Orando S; Orlando R; Angelico F
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD004996. PubMed ID: 17253535
[TBL] [Abstract][Full Text] [Related]
49. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver.
Ferenci P; Dragosics B; Dittrich H; Frank H; Benda L; Lochs H; Meryn S; Base W; Schneider B
J Hepatol; 1989 Jul; 9(1):105-13. PubMed ID: 2671116
[TBL] [Abstract][Full Text] [Related]
50. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis.
El-Kamary SS; Shardell MD; Abdel-Hamid M; Ismail S; El-Ateek M; Metwally M; Mikhail N; Hashem M; Mousa A; Aboul-Fotouh A; El-Kassas M; Esmat G; Strickland GT
Phytomedicine; 2009 May; 16(5):391-400. PubMed ID: 19303273
[TBL] [Abstract][Full Text] [Related]
51. Silymarin: not just another antioxidant.
Camini FC; Costa DC
J Basic Clin Physiol Pharmacol; 2020 Mar; 31(4):. PubMed ID: 32134732
[TBL] [Abstract][Full Text] [Related]
52. [Milk Thistle (Silybum Marianum) as a Supportive Phytotherapeutic Agent in Oncology].
Frassová Z; Rudá-Kučerová J
Klin Onkol; 2017; 30(6):426-432. PubMed ID: 29271213
[TBL] [Abstract][Full Text] [Related]
53. Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases.
Abenavoli L; Izzo AA; Milić N; Cicala C; Santini A; Capasso R
Phytother Res; 2018 Nov; 32(11):2202-2213. PubMed ID: 30080294
[TBL] [Abstract][Full Text] [Related]
54. Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C.
Reddy KR; Belle SH; Fried MW; Afdhal N; Navarro VJ; Hawke RL; Wahed AS; Doo E; Meyers CM;
Clin Trials; 2012 Feb; 9(1):102-12. PubMed ID: 22058086
[TBL] [Abstract][Full Text] [Related]
55. Therapeutic Effects of Milk Thistle (
Doostkam A; Fathalipour M; Anbardar MH; Purkhosrow A; Mirkhani H
Can J Gastroenterol Hepatol; 2022; 2022():2868904. PubMed ID: 35186807
[TBL] [Abstract][Full Text] [Related]
56. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis.
Lirussi F; Mastropasqua E; Orando S; Orlando R
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD005165. PubMed ID: 17253543
[TBL] [Abstract][Full Text] [Related]
57. Poor chemical and microbiological quality of the commercial milk thistle-based dietary supplements may account for their reported unsatisfactory and non-reproducible clinical outcomes.
Fenclova M; Novakova A; Viktorova J; Jonatova P; Dzuman Z; Ruml T; Kren V; Hajslova J; Vitek L; Stranska-Zachariasova M
Sci Rep; 2019 Jul; 9(1):11118. PubMed ID: 31366891
[TBL] [Abstract][Full Text] [Related]
58. Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials.
Liu J; Manheimer E; Tsutani K; Gluud C
Am J Gastroenterol; 2003 Mar; 98(3):538-44. PubMed ID: 12650784
[TBL] [Abstract][Full Text] [Related]
59. [Prevalence of hepatitis B and C viral infection according to the data on fetal outcomes in Moscow in 2015-2017].
Zayratyants OV; Yushchuk ND; Khripun AI; Znoyko OO; Gudkova SB; Orekhov OO; Krasnenkova SF; Zhuravleva AV
Arkh Patol; 2019; 81(2):29-35. PubMed ID: 31006777
[TBL] [Abstract][Full Text] [Related]
60. [A study of the trend of mortality from cirrhosis of the liver in Japan, 1955-79].
Kurashina S; Tango T; Ohbayashi A
Nihon Eiseigaku Zasshi; 1984 Dec; 39(5):819-30. PubMed ID: 6442742
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
